Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
Kintor Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Kintor Pharmaceutical Ltd. published this content on 18 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 April 2023 07:52:09 UTC.